Vertaling van "safety and efficacy " (Frans → Nederlands) :

Analyse de: ‐ Rodrigo G, Castro-Rodriguez J, Plaza V. Safety and efficacy of combined long-acting β-agonists and inhaled
Bespreking van: – Rodrigo G, Castro-Rodriguez J, Plaza V. Safety and efficacy of combined long-acting ß-agonists and inhaled corticosteroids vs long-acting ß-agonists monotherapy for stable COPD. Chest 2009; 136:1029-38

Rodrigo G, Castro-Rodriguez J, Plaza V. Safety and efficacy of combined long-acting -agonists and inhaled corticosteroids
Rodrigo G, Castro-Rodriguez J, Plaza V. Safety and efficacy of combined long-acting ß-agonists and inhaled corticosteroids vs long-acting

BMJ 2004; 329:1317. Lee C, Straus W, Balshaw R et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.
BMJ 2004; 329:1317 Lee C, Straus W, Balshaw R et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials.
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Collaborative Group. Intensive lowering of LDL cholesteriol with 80 mg versus 20 mg simvastatin daily in 12064 survivors of myocardial infarction: a double blind randomized trial.

CSS 8838: Peptide Receptor Radionuclide Therapy “In this advisory report, the Superior Health Council provides a risk assessment (efficacy, toxicity, safety and radioprotection) for Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177 and Yttrium-90 for patients diagnosed with gastroenteropancreatic neuroendocrine tumours.
HGR 8838: Peptide Receptor Radionuclide Therapy “In this advisory report, the Superior Health Council provides a risk assessment (efficacy, toxicity, safety and radioprotection) for Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177 and Yttrium-90 for patients diagnosed with gastroenteropancreatic neuroendocrine tumours.

Dans l’étude PLESS, d’efficacité et de tolérance à long terme (PROSCAR Long-Term Efficacy and Safety Study), les effets de la thérapie par PROSCAR sur les phénomènes urologiques en relation avec l’HBP (intervention chirurgicale (résection transurétrale de la prostate et prostatectomie) ou rétention urinaire nécessitant un cathétérisme) ont été évalués sur une période de 4 ans chez 3016 patients présentant des symptômes modérés à sévères d’HBP.
In PLESS (PROSCAR Long-Term Efficacy and Safety Study), een studie over de efficaciteit en de veiligheid van PROSCAR op lange termijn, werd het effect van een behandeling met PROSCAR op met BPH-gerelateerde urologische complicaties (chirurgische ingreep (bv.transurethrale resectie van de prostaat en prostatectomie) of urineretentie die catheterisatie vereist) gedurende 4 jaar geëvalueerd bij 3016 patiënten met matige tot ernstige symptomen van BPH.

L’efficacité de RotaTeq a été évaluée de deux façons différentes dans une étude clinique contrôlée contre placebo « Rotavirus Efficacy and Safety Trial (REST) ».
De beschermende werkzaamheid van RotaTeq werd op twee manieren beoordeeld in de placebogecontroleerde Rotavirus Efficacy and Safety Trial (REST – werkzaamheids- en veiligheidsonderzoek bij rotavirus).

Une plus large étude RCT en double aveugle, REST (Rotavirus Efficacy and Safety Trial), a
Een uitgebreidere dubbelblinde RCT studie, de zogenaamde REST studie (Rotavirus Efficacy